(SLDB) – All Earnings Related News
-
Solid Biosciences (SLDB) Reports Q4; Announces 2-Year Efficacy and Safety Data from the Ongoing Phase I/II IGNITE DMD Clinical Trial of SGT-001
-
Ultragenyx Pharma (RARE) PT Raised to $178 at SVB Leerink on 2021 Opportunities
-
-
-
-
Back to SLDB Stock Lookup